Circulating Tumor DNA May Predict Clinical Outcomes with First-line, but not Second-line, Immunotherapy for Melanoma
PHILADELPHIA – Baseline levels of circulating tumor DNA (ctDNA) predicted responses to first-line, but not second-line, immune checkpoint inhibition...